$Amylyx Pharmaceuticals (AMLX.US)$ NEWS Amylyx Pharmaceutica...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all participants meeting responder criteria. AMX0035 was well-tolerated and demonstrated promising results, defying the typical disease progression. The trial aims to slow diabetic and visual decline in Wolfram syndrome patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
420Followers
64Following
2715Visitors
Follow